Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026

Reuters10-14

Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026

Clover Biopharmaceuticals Ltd. has announced positive preliminary Phase I clinical data for its combination respiratory PreF vaccine candidates targeting RSV, hMPV, and PIV3, utilizing its Trimer-Tag platform technology. The announcement covers results from two ongoing clinical trials: one in Australia evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in older adults, and another in the U.S. assessing re-vaccination with SCB-1019 in individuals previously vaccinated with GSK's AREXVY. Based on these results, Clover intends to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026. Additional data from the ongoing RSV re-vaccination trial is expected by the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575295780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575295780","market":"nz","top_or_hot":-1,"title":"Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Clover Biopharmaceuticals Ltd. has announced positive preliminary Phase I clinical data for its combination respiratory PreF vaccine candidates targeting RSV, hMPV, and PIV3, utilizing its Trimer-Tag platform technology. The announcement covers results from two ongoing clinical trials: one in Australia evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in older adults, and another in the U.S. assessing re-vaccination with SCB-1019 in individuals previously vaccinated with GSK's AREXVY. Based on these results, Clover intends to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026. Additional data from the ongoing RSV re-vaccination trial is expected by the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Clover Biopharmaceuticals Ltd. has announced positive preliminary Phase I clinical data for its combination respiratory PreF vaccine candidates targeting RSV, hMPV, and PIV3, utilizing its Trimer-Tag platform technology. The announcement covers results from two ongoing clinical trials: one in Australia evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in older adults, and another in the U.S. assessing re-vaccination with SCB-1019 in individuals previously vaccinated with GSK's AREXVY. Based on these results, Clover intends to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026. Additional data from the ongoing RSV re-vaccination trial is expected by the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL1CpmMX:1","article_id":"2575295780","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575295780","pubTimestamp":1760436615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026. Clover Biopharmaceuticals Ltd. has announced positive preliminary Phase I clinical data for its combination respiratory PreF vaccine candidates targeting RSV, hMPV, and PIV3, utilizing its Trimer-Tag platform technology. The announcement covers results from two ongoing clinical trials: one in Australia evaluating SCB-1022  and SCB-1033  in older adults, and another in the U.S. assessing re-vaccination with SCB-1019 in individuals previously vaccinated with GSK's AREXVY. Based on these results, Clover intends to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026. Additional data from the ongoing RSV re-vaccination trial is expected by the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02197":"三叶草生物-B"},"translate_title":"三叶草生物制药公布RSV-HMPV-PIV3联合疫苗I期数据积极，计划2026年开展II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":0.9},"content_text":"Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026\n    \n\n        Clover Biopharmaceuticals Ltd. has announced positive preliminary Phase I clinical data for its combination respiratory PreF vaccine candidates targeting RSV, hMPV, and PIV3, utilizing its Trimer-Tag platform technology. The announcement covers results from two ongoing clinical trials: one in Australia evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in older adults, and another in the U.S. assessing re-vaccination with SCB-1019 in individuals previously vaccinated with GSK's AREXVY. Based on these results, Clover intends to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026. Additional data from the ongoing RSV re-vaccination trial is expected by the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575295780","isCrawlerRequest":true}